摘要
氨氯地平是新型二氢吡啶类钙通道阻滞剂。本文报道应用氨氯地平治疗６０例冠心病高血压患者的结果。第１组单纯口服氨氯地平，第２组口服氨氯地平加上生物反馈治疗，疗程均为８周。治疗结果表明，第１与第２组患者１４种症状的有效率分别为８４．１２％与９４．５％。１４种日常生活能力以及卡氏心功能测定均有明显的改善，但第２组的效果更好（Ｐ＜０．０５）。氨氯地平的降压作用明显，舒张压的下降略逊于收缩压，加用生物反馈治疗后，有效率从８６．６２％增至９３．３４％。在第１与第２组中，心绞痛的发作分别减少了５２．６４％与７０％。
Amlodipine(ALDP) is a new kind of calcium channel blocker of dihydropyridine. This paper presents on the results of the treatment in 60 cases of coronary heart disease and hypertension patients by using ALDP. In the lst group, patients only took ALDP orally, while the patients in the 2nd group were also given biofeedback treatment. Results showed that,the effective rate of 14 symptoms in patients of the lst and 2nd group was 84. 12% and 94.5% respectively, and that 14 activities of daily living and Karnofsky Performance Status all had significant improvement,especially in the 2nd group (P<0. 05).Also,ALDP had a significant effect on reducing blood pressure, in which the reduction of DBP was smaller than SBP, and the effective rate increased from 86.67% to 93. 34% when using biofeedback treatment at the meantime. In addition ,in the lst and 2nd group,the incidence of angina pectoris decreased 52. 64%and 70. 00% respectively.
出处
《中国行为医学科学》
CSCD
1995年第3期145-147,共3页
Chinese Journal of Behavioral Medical Science
关键词
氨氯地平
生物反馈
冠心病
Amlodipine, Hypertension, Angina Pectoris
Biofeedback
